Skip to main content
OpenTrials
Completed

NCT Number: NCT03837730

Citrulline and Arginase Activity in Severe Sepsis and Septic Shock

Sepsis is an acute pathology defined as an inappropriate response of the host to infection, resulting in the onset of organ failure (Quick SOFA ≥2, or SOFA ≥2). Septic shock is a sepsis associated with an elevation of lactate ≥ 2 mmol / l and an arterial hypotension requiring vasoactive drugs. Several studies highlighted that sepsis is associated with a plasma L-arginine deficiency. This deficiency induces a lower availability of L-arginine for multiple metabolic pathways including those involved in the synthesis of nitric oxide (NO) in the vascular endothelium via NO synthase. NO is the main endogenous vasodilator mediator, a lower synthesis induces a vascular and endothelial dysfunction that can promote the occurrence of an organic dysfunction during sepsis. Decrease in available NO was confirmed in patients with sepsis and appears correlated with severity.

L-arginine deficiency can have multiple origins:

* L-arginine deficiency resulting from a decrease in endogenous production from citrulline synthesized by the enterocytes. Such enterocyte dysfunction has been confirmed in patients with sepsis and is characterized biologically by elevated plasma levels of I-FABP (intestinal fatty acid binding protein - enterocyte-specific protein, cytolysis marker) and lower than that of citrulline (hypocitrullinemia, marker of lower activity). * L-arginine deficiency may also result from a catabolism increase via arginase activity increased. This ubiquitous enzyme, having 2 isoforms (Arg1 and Arg2), allows the synthesis of urea and ornithine from L-arginine. An increase in arginase activity would decrease the available reserves of L-arginine for NO synthesis.

The objectives of this work is to evaluate, in patients with severe sepsis or septic shock, the prognostic value of the plasma arginase activity and the plasma expression of 2 isoforms Arg1 and Arg2, their kinetics, and the link between activity / expression of arginase and enterocyte dysfunction.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de BESANCON

Besançon, 25030, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years old or older
  • Patient admitted to ICU
  • Diagnosis, suspected or confirmed, of severe sepsis or septic shock
  • Expected ICU stay of at least 2 days
  • Affiliation to a social security system or recipient of a such system
  • Signed informed consent

Exclusion criteria

  • Pregnancy
  • Chronic intestinal pathology
  • Chronic renal failure defined by creatinine clearance <50 ml / min / 1.73m2 (CKD-EPI)
  • Severe hepatic insufficiency (Child-Pugh stage C score)
  • Legal incapacity or limited legal capacity
  • Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator
  • Patient within the exclusion period of another study or planned by the "national file of volunteers"

Treatment and study plan

Primary outcomes

  1. prognostic value of plasma arginase activity and expression at ICU admission in patients with severe sepsis or septic shock

    Time frame: 28 days

    activity / expression of plasma arginase at ICU admission and 28-day mortality rate from admission to intensive care

Secondary outcomes

  1. activity / expression kinetic of plasma arginase

    Time frame: during the first 7 days of ICU admission

    3 points kinetic : admission, day 3 and day 7

  2. prognostic value of enterocyte damage

    Time frame: 28 days

    at ICU admission and 28-day mortality rate from admission to intensive care

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Besancon

Other

Registry information

Official study title

Activity and Expression of Plasma Arginase in Patients With Severe Sepsis or Septic Shock as Prognostic Value

Acronym: CARS

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Feb 12, 2019
Registry last updated
Jan 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.